WEI Zilong,ZHAO Chenyi,QIAO Mingliang,et al.Research progress of Qifu yin in the treatment of Alzheimer’s disease with marrow-sea insufficiency syndrome[J].ZHONGGUO YAOFANG,2026,37(10):1376-1380.
WEI Zilong,ZHAO Chenyi,QIAO Mingliang,et al.Research progress of Qifu yin in the treatment of Alzheimer’s disease with marrow-sea insufficiency syndrome[J].ZHONGGUO YAOFANG,2026,37(10):1376-1380.DOI: 10.6039/j.issn.1001-0408.2026.10.24.
Research progress of Qifu yin in the treatment of Alzheimer’s disease with marrow-sea insufficiency syndrome
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder. Marrow-sea insufficiency serves as the fundamental basis for the onset of AD. Early syndrome differentiation-based intervention helps to delay disease progression, and improve patients’ cognitive function. Qifu yin is a representative specialized prescription for AD with marrow-sea insufficiency syndrome. Studies demonstrate that Qifu yin exerts neuroprotective effects through multiple pathways, including inhibiting the abnormal deposition of amyloid
β
-protein and hyperphosphorylation of tau protein, alleviating neuroinflammation, regulating oxidative stress and mitochondrial dysfunction, modulating the cholinergic system, and improving synaptic plasticity. Qifu yin combined with Western medicine such as donepezil, memantine, and butylphthalide, or combined with external therapies such as acupuncture, can effectively improve cognitive function and activities of daily living in AD patients with favorable safety. Future research should focus on the core pathogenesis and key targets of AD with marrow-sea insufficiency syndrome, provide in-depth elucidation of the scientific connotation of Qifu yin’s “tonifying the kidney to produce marrow”, and further conduct high-quality clinical studies to provide scientific evidence for the prevention and treatment of AD with marrow-sea insufficiency syndrome.
关键词
Keywords
references
LANE C A , HARDY J , SCHOTT J M . Alzheimer’s di-sease [J ] . Euro J Neurology , 2018 , 25 ( 1 ): 59 - 70 .
YIN M F , DING S T , ZHAO M L , et al . The global,regional,and national burden and attributable risk factors of Alzheimer’s disease and other dementias,1990-2021:a systematic analysis for the Global Burden of Disease Study [J ] . J Alzheimer’s Dis , 2025 , 107 ( 1 ): 192 - 206 .
YANG Y X , QIU L N . Research progress on the pathogene-sis,diagnosis,and drug therapy of Alzheimer’s disease [J ] . Brain Sci , 2024 , 14 ( 6 ): 590 .
Jr JACK C R , ANDREWS J S , BEACH T G , et al . Revised criteria for diagnosis and staging of Alzheimer’s di-sease:Alzheimer’s Association Workgroup [J ] . Alzheimers Dement , 2024 , 20 ( 8 ): 5143 - 5169 .
LIU E J , ZHANG Y , WANG J Z . Updates in Alzheimer’s disease:from basic research to diagnosis and therapies [J ] . Transl Neurodegener , 2024 , 13 ( 1 ): 45 .
BUSCHE M A , HYMAN B T . Synergy between amyloid-β and tau in Alzheimer’s disease [J ] . Nat Neurosci , 2020 , 23 ( 10 ): 1183 - 1193 .
ALQAHTANI S M , AL-KURAISHY H M , AL GAREEB A I , et al . Unlocking Alzheimer’s disease:the role of BDNF signaling in neuropathology and treatment [J ] . Neuromol Med , 2025 , 27 ( 1 ): 36 .
YANG X Z , YE T Y , HE Y , et al . Qi-fu-Yin attenuated cognitive disorders in 5xFAD mice of Alzheimer’s di-sease animal model by regulating immunity [J ] . Front Neurol , 2023 , 14 : 1183764 .
XIAO Q Y , YE T Y , WANG X L , et al . A network pharmacology-based study on key pharmacological pathways and targets of Qi Fu Yin acting on Alzheimer’s di-sease [J ] . Exp Gerontol , 2021 , 149 : 111336 .
POPESCU C , MUNTEANU C , ANGHELESCU A , et al . Novelties on neuroinflammation in Alzheimer’s disease:focus on gut and oral microbiota involvement [J ] . Int J Mol Sci , 2024 , 25 ( 20 ): 11272 .
HE C X , YU W J , YANG M , et al . Qi Fu Yin ameliorates neuroinflammation through inhibiting RAGE and TLR4/NF-κB pathway in AD model rats [J ] . Aging , 2023 , 15 ( 22 ): 13239 - 13264 .
CHENG J H , LI W J , WANG L L , et al . Jiawei qifuyin enhances immunity and improves cognitive impairment in APP/PS1 mice through modulation of neuroinflammatory pathways [J ] . J Inflamm Res , 2024 , 17 : 9021 - 9040 .
LI X , WU Z Y , SI X Y , et al . The role of mitochondrial dysfunction in the pathogenesis of Alzheimer’s disease and future strategies for targeted therapy [J ] . Eur J Med Res , 2025 , 30 ( 1 ): 434 .
WANG S L , HUANG J , CHEN Y T , et al . Qifu-Yin activates the Keap1/Nrf2/ARE signaling and ameliorates synaptic injury and oxidative stress in APP/PS1 mice [J ] . J Ethnopharmacol , 2024 , 333 : 118497 .
KARAMI A , DARREH-SHORI T , SCHULTZBERG M , et al . CSF and plasma cholinergic markers in patients with cognitive impairment [J ] . Front Aging Neurosci , 2021 , 13 : 704583 .
RENNIE K . Neuronal and glial α7 nicotinic acetylcholine receptors:role in Alzheimer’s disease pathophysiology [J ] . Life , 2025 , 15 ( 7 ): 1032 .
CHENG Q , FAN Y O , ZHANG P F , et al . Biomarkers of synaptic degeneration in Alzheimer’s disease [J ] . Ageing Res Rev , 2025 , 104 : 102642 .
KIVISÄKK P , CARLYLE B C , SWEENEY T , et al . Increased levels of the synaptic proteins PSD-95,SNAP-25,and neurogranin in the cerebrospinal fluid of patients with Alzheimer’s disease [J ] . Alzheimers Res Ther , 2022 , 14 ( 1 ): 58 .
GREEN R C . Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease:a randomized controlled trial [J ] . JAMA , 2009 , 302 ( 23 ): 2557 .
HUANG Q , LUO D , CHEN L , et al . Effectiveness of acupuncture for Alzheimer’s disease:an updated systematic review and meta-analysis [J ] . Curr Med Sci , 2019 , 39 ( 3 ): 500 - 511 .